Genmab — Januar 2013
-
Celgene har lige kommet med deres 2013 guidiance.
-
De guider 4,3 mia. $ i Revlimid salg alene
-
-
-
Det er super med disse studier. Er der nogle som har lavet en opgørelse af hvor mange studier der er "ongoing" med ofa hvert kvartal ??
-
For på den måde at bedømme royalty indtægter?
-
-
-
Jeg ser på denne graf i realtid pt. Credit suisse har 55 K i + over 220 handelsdage.. Så det er nok hvad de maks mangler at afhænde i +81 niveau
-
I får lige en realtidsgraf her: http://www.proinvestor.com/index.php?p=debat_post&postid=63351
-
-
Blogger lidt fra jpm. Men kun casual
-
Han speedtalker gennem arzerra pipeline
-
Daratumumab nu. Short rapid development program
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind